<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564898</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2020-000923-37</org_study_id>
    <nct_id>NCT04564898</nct_id>
  </id_info>
  <brief_title>Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.</brief_title>
  <acronym>TriComB</acronym>
  <official_title>A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim oh this study is to determine the safety and recommended dose of&#xD;
      trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation&#xD;
      phase) and to assess its activity in previously untreated mCRC patients who are deemed not&#xD;
      eligible for intensive chemotherapy (part 2, expansion phase).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, phase 1/2 study evaluating the safety and activity of&#xD;
      trifluridine/tipiracil in combination with capecitabine and bevacizumab in mCRC. The first&#xD;
      part (Part 1) of the study will consist in a dose-escalation assessment of the safety of the&#xD;
      treatment in subjects with previously untreated mCRC deemed not fit for irinotecan- and/or&#xD;
      oxaliplatin- based regimens (i. e. FOLFOX/XELOX/FOLFIRI/FOLFOXIRI with or without targeted&#xD;
      agents).&#xD;
&#xD;
      The second part (Part 2) will be an open-label phase 2 study with a Fleming's single-stage&#xD;
      design to evaluate the ORR of the study treatment at the recommended dose established in the&#xD;
      first part of the study in the same patients' population.&#xD;
&#xD;
      Trifluridine/tipiracil, capecitabine and bevacizumab will be administered in 28-days cycles&#xD;
      until progressive disease, unacceptable toxicities, or patients' refusal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recommended dose</measure>
    <time_frame>2 years</time_frame>
    <description>recommended dose of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>activity</measure>
    <time_frame>3 years</time_frame>
    <description>activity of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of overaal response rate per RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life for cancer patients</measure>
    <time_frame>3 years</time_frame>
    <description>quality of life as measured by EORTC QLQ-C30 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life for colorectal cancer patients</measure>
    <time_frame>3 years</time_frame>
    <description>quality of life as measured by EORTC QLQ-CR29 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life for dimensions health</measure>
    <time_frame>3 years</time_frame>
    <description>quality of life as measured by EuroQol EQ-5D questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>3 years</time_frame>
    <description>efficacy of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of progression-free survival and overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>bioavailability</measure>
    <time_frame>2 years</time_frame>
    <description>Absolute and relative bioavailability of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Steady state concentration</measure>
    <time_frame>2 years</time_frame>
    <description>Steady state concentration of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Therapeutic index</measure>
    <time_frame>2 years</time_frame>
    <description>Therapeutic index of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>2 years</time_frame>
    <description>Volume of distribution of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Half-life</measure>
    <time_frame>2 years</time_frame>
    <description>Plasma half-life of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance</measure>
    <time_frame>2 years</time_frame>
    <description>Clearance of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>trifluridine/tipiracil plus capecitabine and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days&#xD;
Part 2&#xD;
• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days</description>
    <arm_group_label>trifluridine/tipiracil plus capecitabine and bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days&#xD;
Part 2&#xD;
• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days</description>
    <arm_group_label>trifluridine/tipiracil plus capecitabine and bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine/Tipiracil</intervention_name>
    <description>Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days&#xD;
Part 2&#xD;
• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days</description>
    <arm_group_label>trifluridine/tipiracil plus capecitabine and bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to study procedures.&#xD;
&#xD;
          -  Histologically proven diagnosis of colorectal cancer.&#xD;
&#xD;
          -  Metastatic colorectal cancer not previously treated with chemotherapy for metastatic&#xD;
             disease.&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST1.1.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG PS ≤ 1.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Previous adjuvant fluoropyrimidine-based chemotherapy allowed only if more than 12&#xD;
             months elapsed between the end of adjuvant and first relapse.&#xD;
&#xD;
          -  Availability of archival tumour tissue (primary tumour and metastases or at least one&#xD;
             of the two) for biomarker analysis.&#xD;
&#xD;
          -  Availability of blood sample for biomarker analysis.&#xD;
&#xD;
          -  Previously not eligible for a chemotherapy doublet or triplet (oxaliplatin and/or&#xD;
             irinotecan-based combination).&#xD;
&#xD;
          -  Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hemoglobin ≥ 9 g/dl.&#xD;
&#xD;
          -  Total bilirubin ≤1.5 fold the upper-normal limits (UNL), AST (SGOT) and/or ALT (SGPT)&#xD;
             ≤ 2.5 x UNL (or &lt;5 x UNL in the case of liver metastases), alkaline phosphatase ≤ 2.5&#xD;
             x UNL (or &lt;5 x UNL in case of liver metastases).&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min or serum creatinine ≤1.5 x UNL.&#xD;
&#xD;
          -  Male subjects with female partners of childbearing potential must be willing to use&#xD;
             adequate contraception as approved by the investigator (barrier contraceptive measure&#xD;
             or oral contraception).&#xD;
&#xD;
          -  Women of childbearing potential must have a negative blood pregnancy test at the&#xD;
             baseline visit. For this trial, women of childbearing potential are defined as all&#xD;
             women after puberty, unless they are postmenopausal for at least 12 months, are&#xD;
             surgically sterile, or are sexually inactive.&#xD;
&#xD;
          -  Subjects and their partners must be willing to avoid pregnancy during the trial and&#xD;
             until 6 months after the last trial treatment.&#xD;
&#xD;
          -  Will and ability to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiotherapy to any site within 4 weeks before the study.&#xD;
&#xD;
          -  Previous treatment with trifluridine/tipiracil, bevacizumab and capecitabine (previous&#xD;
             treatment with capecitabine was permitted only in the adjuvant setting and if more&#xD;
             than 12 months elapsed between the end of adjuvant and first relapse).&#xD;
&#xD;
          -  Untreated brain metastases or spinal cord compression or primary brain tumors.&#xD;
&#xD;
          -  History or evidence upon physical examination of CNS disease unless adequately&#xD;
             treated.&#xD;
&#xD;
          -  Clinical signs of malnutrition.&#xD;
&#xD;
          -  Active uncontrolled infections or other clinically relevant concomitant illness&#xD;
             contraindicating chemotherapy administration.&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive&#xD;
             encephalopathy.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease for example&#xD;
             cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable&#xD;
             angina, New York Heart Association (NYHA) grade II or greater congestive heart&#xD;
             failure, serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          -  Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent&#xD;
             arterial thrombosis) within 6 months of study enrolment.&#xD;
&#xD;
          -  Any previous venous thromboembolism ≥ NCI CTCAE Grade 4.&#xD;
&#xD;
          -  History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI&#xD;
             bleeding within 6 months prior to the first study treatment.&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days prior to enrolment or 2&#xD;
             investigational agent half-lives (whichever is longer).&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of localized basal and squamous cell carcinoma or cervical cancer in&#xD;
             situ.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, malabsorption&#xD;
             syndrome, or inability to take oral medication.&#xD;
&#xD;
          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of&#xD;
             the trial drugs.&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drugs according to the&#xD;
             product information of the pharmaceutical companies.&#xD;
&#xD;
          -  Pregnant or lactating women. Women of childbearing potential with either a positive or&#xD;
             no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at&#xD;
             least 12 months to be considered of non-childbearing potential. Sexually active males&#xD;
             and females (of childbearing potential) unwilling to practice contraception (barrier&#xD;
             contraceptive measure or oral contraception) during the study and until 6 months after&#xD;
             the last trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiara Cremolini, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione GONO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Cremolini, MD, PhD</last_name>
    <phone>+39.050.992192</phone>
    <email>chiaracremolini@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Delliponti, MD</last_name>
    <phone>+39.050.992192</phone>
    <email>tricombstudy@gmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

